Jane Street
RPRX icon

Jane Street’s Royalty Pharma RPRX Stock Holding History

Jane Street’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3M Sell
53,460
-2,346,922
-98% -$122M ﹤0.01% 4512
2026
Q1 		$115M Sell
2,400,382
-2,547,027
-51% -$112M 0.01% 580
2025
Q4 		$191M Buy
4,947,409
+1,795,749
+57% +$68.5M 0.03% 371
2025
Q3 		$111M Buy
3,151,660
+2,391,538
+315% +$86.6M 0.02% 541
2025
Q2 		$27.4M Sell
760,122
-304,051
-29% -$10.1M 0.01% 1165
2025
Q1 		$33.1M Buy
1,064,173
+779,246
+273% +$24.7M 0.01% 932
2024
Q4 		$7.27M Buy
284,927
+79,121
+38% +$2.1M ﹤0.01% 2205
2024
Q3 		$5.82M Sell
205,806
-77,611
-27% -$2.15M ﹤0.01% 2623
2024
Q2 		$7.47M Buy
283,417
+193,416
+215% +$5.36M ﹤0.01% 2387
2024
Q1 		$2.73M Sell
90,001
-327,258
-78% -$9.65M ﹤0.01% 3554
2023
Q4 		$11.7M Buy
417,259
+342,561
+459% +$9.41M ﹤0.01% 1778
2023
Q3 		$2.03M Sell
74,698
-53,439
-42% -$1.59M ﹤0.01% 4034
2023
Q2 		$3.94M Buy
128,137
+90,804
+243% +$3.08M ﹤0.01% 3082
2023
Q1 		$1.35M Buy
37,333
+9,517
+34% +$353K ﹤0.01% 4473
2022
Q4 		$1.1M Buy
27,816
+9,166
+49% +$383K ﹤0.01% 4847
2022
Q3 		$749K Buy
18,650
+12,860
+222% +$549K ﹤0.01% 5943
2022
Q2 		$243K Sell
5,790
-582
-9% -$23.9K ﹤0.01% 7921
2022
Q1 		$248K Sell
6,372
-27,987
-81% -$1.1M ﹤0.01% 8696
2021
Q4 		$1.37M Sell
34,359
-6,206
-15% -$241K ﹤0.01% 5274
2021
Q3 		$1.47M Sell
40,565
-32,142
-44% -$1.25M ﹤0.01% 5124
2021
Q2 		$2.98M Buy
72,707
+53,870
+286% +$2.29M ﹤0.01% 3583
2021
Q1 		$822K Buy
18,837
+12,646
+204% +$600K ﹤0.01% 5843
2020
Q4 		$310K Buy
+6,191
New +$263K ﹤0.01% 6359
2020
Q3 		– Sell
-42,425
Closed -$1.82M – 7810
2020
Q2 		$2.06M Buy
+42,425
New +$2.1M ﹤0.01% 3026

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street's RPRX Position: Q2 2026 in Review

Jane Street reduced its Royalty Pharma (RPRX) stake by 98% in Q2 2026, selling an estimated $122M and leaving 53,460 shares worth $3M. The position accounts for ﹤0.01% of the portfolio, ranked #4512.

Jane Street first reported a position in RPRX in Q2 2020 and has held it in 24 quarters since. The position peaked at $191M in Q4 2025. 642 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Jane Street held 53,460 shares of Royalty Pharma worth $3M as of Q2 2026.
  • Jane Street sold 2,346,922 Royalty Pharma shares in Q2 2026, an estimated $122M.
  • Royalty Pharma made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #4512 holding.
  • Jane Street first reported a position in Royalty Pharma in Q2 2020 and has held it in 24 quarters since.
  • Jane Street's Royalty Pharma position peaked at $191M in Q4 2025.
  • 642 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.